CR Bard Inc. (NYSE: BCR) is a large market cap stock with a market cap of 17196.96. It is in the Medical Instruments & Supplies industry and sector Healthcare, with a current P/E of 102.7, a forward P/E of 20.64 and EPS of 2.26. At a stock price of 232.35 (0.20%) it has a dividend yield of 0.45%.
EPS growth for the last five years have been -19.80%, more recently this last year it has grown by -52.90%. The next year growth is going to be about 10.74% and more long-term 10.80% after five years. EPS growth quarter over quarter is -16.70%. Sales growth for the past five years have been 4.70% and sales growth quarter over quarter is 6.60%.
For performance, CR Bard Inc. the past week has seen a gain of -2.12%. For the last month performance for CR Bard Inc. is 3.15%. While the last quarter is 11.36% and half year, 31.54%. Finally for the year, performance is 30.30%.
The 52-week high for CR Bard Inc., is at -2.85%, and for the 52-week low it comes to a value of 35.41%. The 20-day simple moving average is 2.99% and 16.48% for the 200-day simple moving average.
Volatility for the week is at 1.22%, and for the month it is 1.26%. CR Bard Inc., has a target price of 231.
In terms of debt, long term debt/equity is 0.78, and for total debt/equity CR Bard Inc. has 1.14. The gross margin is 62.20%, while operating margin is *TBA, the profit margin is *TBA. The current ratio is 1.5 and the quick ratio is 1.2.
Insider ownership is at 0.50%, with instituitional ownership at 90.90%. CR Bard Inc. has a payout ratio of *TBA. With the total shares outstanding coming to 74.16. The shares float is 73.18, with the float short at 1.70%, with short ratio coming to 2.6.
In terms of returns, the return on assets see CR Bard Inc., get *TBA, with its returns on investment at 6.40%. Return on equity is *TBA. So will the investors see the target price of 231, reached soon?
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.